期刊文献+

骨保护素作为预测心血管疾病发病率和死亡率的新标志物的研究进展 被引量:5

原文传递
导出
摘要 骨保护素(osteoprotegerin,OPG)是1997年Tsuda等[1]在人胚胎肺纤维细胞中发现的一种分泌蛋白,是肿瘤坏死因子受体(TNFR)超家族的一员,具有调节骨密度的作用。
出处 《中华临床医师杂志(电子版)》 CAS 2011年第10期2963-2966,共4页 Chinese Journal of Clinicians(Electronic Edition)
基金 军队医学科技创新项目资助(09MA094)
  • 相关文献

参考文献1

二级参考文献21

  • 1向光大,曹红燕,曾尟枚,赵林双.1型糖尿病患者胰岛素治疗前后内皮依赖性血管舒张功能的变化[J].中国糖尿病杂志,2006,14(2):109-111. 被引量:5
  • 2Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 1997, 89: 309-319.
  • 3Zhang J, Fu M, Myles D, et al. PDGF induces osteoprotegerin expression in vascular smooth muscle ceils by multiple signal pathways. FEBS letters, 2002, 521 : 180-184.
  • 4Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation, 2002, 106 : 1192-1194.
  • 5Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab, 2003, 88: 1024-1028.
  • 6Knudsen ST, Foss CH, Poulsen PL, et al. Increased plasma concentrations of osteoprotegerin in type 2 diabetic patients with microvascular complications. Eur J Endocrinol, 2003, 149 : 39- 42.
  • 7Avignon A, Sultan A, Plot C, et al. Osteoprotegerin is associated with silent coronary artery disease in high-risk but asymptomatic type 2 diabetic patients. Diabetes Care, 2005, 28: 2176-2180.
  • 8Galluzzi F, Stagi S, Salti R, et al. Osteoprotegerin serum levels in children with type 1 diabetes: a potential modulating role in bone status. Eur J Endocrinol, 2005, 153 : 879-885.
  • 9Xiang GD, Wu YH. Apolipoprotein e4 allele and endotheliumdependent arterial dilation in type 2 diabetes mellitus without angiopathy. Diabetologia, 2003, 46: 514-519.
  • 10Xiang GD, Wang YL. Regular aerobic exercise training improves endothelium-dependent artery dilation in patients with impaired fasting glucose. Diabetes Care, 2004, 27:801-802.

共引文献31

同被引文献67

  • 1尚玉红,洪秀芳,吴鹏,马合木达.冠心病中医辨证与QT和JT离散度的关系[J].中国中西医结合急救杂志,2005,12(2):87-90. 被引量:17
  • 2柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2157
  • 3Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2008,51 : 210-247.
  • 4Simonet WS, Lacey DL, Dunstan GR, et al. Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell, 1997,89:309-319.
  • 5Tsuda E, Goto M, Mochizuki S, et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun, 1997, 234: 137-142.
  • 6Soufi M, Schoppet M, Sattler AM, et al. Osteoprotegerin gene polymorphisms in men with coronary artery disease. J Clin Endocrinol Metab, 2004,89: 3764-3768.
  • 7Ueland T, Wilson SG, Amirul Islam FM, et al. A cohort study of the effects of serum osteoprotegerin and osteoprotegerin gene polymorphisms on cardiovascular mortality in elderly women. Clin Endocrinol (Oxf), 2009,71 : 828-833.
  • 8Celczyfiska Bajew L, Horst Sikorska W, Bychowiec B, et al. The effects of osteoprotegerin (OPG) gene polymorphism in patients with ischaemic heart disease on the morphology of coronary arteries and bone mineral density. Kardiol Pol, 2011,69:573-578.
  • 9Price PA, June HH,Buckley JR,et al. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol,2001,21 : 1610-1616.
  • 10Bennett B J, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol,2006,26:2117-2124.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部